Gregory lab #PhD student, Lauren Whaley Powers, attended #SNO25 in beautiful Honolulu & presented her poster:

'Integrative #SingleNuclei #SpatialTranscriptomic profiling of primary and recurrent human #GBM reveals cell-type specific #EGFRvIII expression & #ANXA1 signaling axis' 🧠🧬🔬💻🌺

18F-Fluciclovine Imaging Differentiates Progression From Treatment-Related Changes in Brain Metastases | OncLive 18F-Fluciclovine PET/MRI detected disease progression and ruled out disease in non-progressors among patients with solid tumor brain metastases.

8F-Fluciclovine Imaging Differentiates Progression From Treatment-Related Changes in Brain Metastases @uwsph.bsky.social @neuroonc.bsky.social #SNO25 #oncology www.onclive.com/view/18f-flu...

Erdafitinib Is Safe and Shows Preliminary Efficacy in F3T3 Fusion+ Glioma | OncLive Erdafitinib had a safety profile that was deemed tolerable in patients with recurrent or progressive IDH wild-type glioma harboring F3T3 gene fusions.

Erdafitinib Is Safe and Shows Preliminary Efficacy in F3T3 Fusion+ Glioma @neuroonc.bsky.social #SNO25 #oncology www.onclive.com/view/erdafit...

CAR T-Cell Therapy Proves Safe in Recurrent Brain/Leptomeningeal Mets From HER2+ Breast Cancer | OncLive HER2-directed CAR T-cell therapy was safe in patients with brain/leptomeningeal metastases from HER2-positive breast cancer.

CAR T-Cell Therapy Shows Early Safety in Recurrent Brain/Leptomeningeal Mets From HER2+ Breast Cancer
@cityofhope.bsky.social @neuroonc.bsky.social #SNO25 #bcsm #oncology www.onclive.com/view/car-t-c...

B7-H3–Directed CAR T-Cell Therapy Has Acceptable Safety Profile in Recurrent Glioblastoma | OncLive B7-H3–directed CAR T-cell therapy given intraventricularly was well tolerated and showed early efficacy signals in patients with recurrent glioblastoma.

B7-H3–Directed CAR T-Cell Therapy Has Acceptable Safety Profile in Recurrent Glioblastoma @uncdeptmedicine.bsky.social @unclineberger.bsky.social #SNO25 #oncology www.onclive.com/view/b7-h3-d...

Mirdametinib Generates Responses and Is Safe in Pediatric Low-Grade Glioma | OncLive Mirdametinib had clinical activity and was deemed well tolerated in MEK inhibitor–naive pediatric patients with recurrent/progressive low-grade glioma.

Mirdametinib Generates Responses and Is Safe in Pediatric Low-Grade Glioma @stjude.bsky.social @neuroonc.bsky.social #SNO25 #oncology #glioma #braincancer www.onclive.com/view/mirdame...